16 nM) inhibitor

Cat. No JK1868028_10_MG

Vendor: J&K Chemical

Product Information

Product Name

Brand Name

J&K

Product Number

1868028

CAS

1202916-90-2

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

44545852

IUPAC Name

(3E)-5-chloro-3-5-3-(4-methyl-1,4-diazepane-1-carbonyl)phenylfuran-2-ylmethylidene-1H-indol-2-one

InChI Key

KGBPLKOPSFDBOX-CJLVFECKSA-N

SMILES

CN1CCCN(CC1)C(=O)C2=CC=CC(=C2)C3=CC=C(O3)/C=C/4\C5=C(C=CC(=C5)Cl)NC4=O

Safety Information

Storage Condition

Freezer -20℃

References

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2021-02-04

DOI: 10.1021/acs.jmedchem.0c01467

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle

Publication Name: ACS Chemical Biology

Publication Date: 2020-05-27

DOI: 10.1021/acschembio.0c00343

Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity

Publication Name: Cancer Research

Publication Date: 2020-02-14

DOI: 10.1158/0008-5472.can-19-2330

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Publication Name: European Urology

Publication Date: 2018-11

DOI: 10.1016/j.eururo.2018.06.020

CX-6258, 99%, a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor

Product Information

General Information

Safety Information

References

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle

Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy